Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Dr. Zhou mainly focused on the development of highly efficient synthetic strategies to construct “drug-like” compound libraries for the discovery of lead compounds against the age-related diseases, such as Alzheimer’s disease, benign prostatic hyperplasia, depressive disorders, cancer etc. He has published more than 80 academic papers in peer-review journals, such as Chem Rev, J Med Chem and ACS Catal., etc and applied 20 patents. He has also received prizes such as the CPA-Servier Young Investigator Awards in Medicinal Chemistry, Sanofi-SIBS 2016 Young Faculty Award and the outstanding member of Youth Innovation Promotion Association of Chinese Academy of Sciences.

Education

09/1999 - 07/2003, B.S. in Pharmaceutical Engineering, Shenyang Pharmaceutical University

09/2003 - 07/2008, Ph.D. in Medicinal Chemistry, Shenyang Pharmaceutical University

Work Experience

07/2008 – 07/2010, Post-doctor, Shanghai Institute of Materia Medica, CAS

09/2010 – 09/2016, Associate Professor, Shanghai Institute of Materia Medica, CAS

09/2016 – Present, Professor, Shanghai Institute of Materia Medica, CAS

Research Directions

Medicinal Chemistry, Innovative Drug Discovery, Highly Efficient Synthetic Strategy

Grants & Research Projects

Achievements

(1)An AChE inhibitor for AD entered into Phase I trials

(2)An α1A-AR antagonist for benign prostatic hyperplasia entered into Phase I trials

(3)Constructed diversified drug-like compound libraries by developing highly efficient synthetic Strategies

morefold

Social Titles

morefold

Awards & Honors

morefold

Pubilcations

Full Publication List

Selected Publications

1.Qiaolan Yang, Chenglin Wu, Jianhui Zhou, Guoxue He, Hong Liu* and Yu Zhou*. Highly selective C–H bond activation of N-arylbenzimidamide and divergent couplings with diazophosphonate compounds: a catalyst-controlled selective synthetic strategy for 3-phosphorylindoles and 4-phosphorylisoquinolines. Org. Chem. Front. 2019, 6, 393-398.

2.Chenglin Wu, Jianhui Zhou, Guoxue He, Huihui Li, Qiaolan Yang, Run Wang, Yu Zhou* and Hong Liu*. Ruthenium(II)-Catalyzed Selective C-H Bond Activation of Imidamides and Coupling with Sulfoxonium Ylides: An Efficient Approach for the Synthesis of Highly Functional 3-Ketoindoles. Org. Chem. Front. 2019, 6, 1183-1188.

3.Jianhui Zhou, Jian Li, Yazhou Li, Chenglin Wu, Guoxue He, Qiaolan Yang, Yu Zhou* and Hong Liu*. Direct Synthesis of 3-Acylindoles through Rhodium(III)-Catalyzed Annulation of N-Phenylamidines with α-Cl Ketones. Org. Lett. 2018, 20, 7645-7649.

4.Feifei Fang, Chunmei Zhang, Chaofan Zhou, Yazhou Li, Yu Zhou* and Hong Liu*. Rh(III)-Catalyzed C-H Activation of Benzoylacetonitriles and Tandem Cyclization with Diazo Compounds to Substituted Benzo[ de]chromenes. Org. Lett. 2018, 20, 1720-1724.

5.Chaofan Zhou, Feifei Fang, Yilang Cheng, Yazhou Li, Hong Liu* and Yu Zhou*. Rh(III)‐Catalyzed C‐H Activation of Benzoylacetonitriles and Cyclization with Sulfoxonium Ylides to Naphthols. Adv. Synth. Catal. 2018, 360 (13), 2546-2551.

6.Yazhou Li, Jianhui Zhou, Feifei Fang, Bin Xu, Hong Liu* and Yu Zhou*. Rhodium(III)-Catalyzed C-H Activation of alpha-Iminonitriles or alpha-Imino Esters and Cyclization with Acrylates to 2 H-Isoindoles. J. Org. Chem. 2018, 83, 11736-11746.

7.Xiaowei Wu, Bao Wang, Shengbin Zhou, Yu Zhou* and Hong Liu.* Ruthenium-Catalyzed Redox-Neutral [4+1] Annulation of Benzamides and Propargyl alcohols via C-H Bond Activation. ACS Catal. 2017, 7, 2494–2499.

8.Wenjing Xia, Hong Yao, Dan Liu, Linxiang Zhao, Yu Zhou* and Hong Liu*. Enantioselective N-Heterocyclic Carbene-Catalyzed [3+3] Annulation of α,β-Unsaturated Esters with Methyl Ketoimine. Adv. Synth. Catal. 2016, 358, 1864-1869.

9.Yu Zhou, Jiang Wang, Zhanni Gu, Shuni Wang,Wei Zhu, Jose Acena,Vadim Soloshonok, Kunisuke Izawa, Hong Liu*. Next Generation of Fluorine-containing Pharmaceuticals Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies; New Structural Trends and Therapeutic Areas. Chem. Rev. 2016, 116, 422–518.

10.Yu Zhou, Jun Liu, Mingyue Zheng, Shuli Zheng, Chunyi Jiang, Xiaomei Zhou, Dong Zhang, Jihui Zhao, Deju Ye, Mingfang Zheng, Hualiang Jiang, Dongxiang Liu, Jian Cheng and Hong Liu. Structural optimization and biological evaluation of 1,5-disubstituted pyrazole-3-carboxamines as potent inhibitors of human 5-lipoxygenase. Acta Pharmaceutica Sinica B. 2016, 6, 32–45.

morefold